Abstract:Tumor metastasis has become a fatal disease progress which greatly influence cancer treatment and prognosis. Generally, the metastatic progression can be classified into three main processes: the cancer cells leave the original “tumor home”, travel through “vessel highway”, and settle down in a new “tissue house”. Many agents with various machnisms have been developed for the treatment of cancer cell metastasis, including VEGFR inhibitors, integrin inhibitors, or MMP (matrix metallo protease) inhibitors. Recently a growing interest has been shown for the CXC chemokine receptor 2 (CXCR2), due to their involvement in metastasis physiology. Once CXCR2 is triggered by upstream effectors, it can cause the activation of downstream signals such as serine/threonine kinases, tyrosine kinases. Its essential role in influencing tumor microenvironment makes CXCR2 an important target for anti-tumor metastasis treatment. The first non-peptide CXCR2 antagonist SB225002 was discovered in the mid-1990s by GSK Company. To date, four drug candidates are in clinical trials, including Danirixin, AZD5069, Reparixin and Ladarixin. The clinical indications of AZD5069 were expanded to metastatic head & neck cancer and metastatic pancreatic cancer, in combination with MEDI4736 (a PDL-1 inhibitor). As an excellent computational tool, the pharmacophore model, has been rapidly developed for the identification of novel hit/lead compounds for various targets, especially for proteins without crystal structures. An extensive effort has been made in the attempt to apply pharmacophore model to identify novel VEGFR inhibitors, MMP inhibitors as anti-cancer metastasis agents, revealing that ligand-based pharmacophore model is the best approach when the target geometry is not available, or the binding mode is not elucidated. At present, the binding mode of CXCR2 with its antagonists has not been fully discovered, however, the group of N. Neamati have been trying to establishing a ligand-based pharmacophore model which could be applied for virtual screening to find novel scaffolds of CXCR2 antagonist; this work, for the first time, indicated the feasibility of applying pharmacophore model for the discovery of CXCR2 antagonist. Although a bunch of CXCR2 antagonists have been identified, the anti-tumor metastasis effect of CXCR2 antagonists is not considered in most cases. In our study, a convenient pharmacophore model was built with HipHop program, by screening a mini-database contained compounds which were designed based on the known structure-activity relationship (SAR) of the diarylurea series CXCR2 antagonists. Several novel skeletons with moderate to potent CXCR2 antigonitic activiites were identified. Following optimization resulted in the discovery of compound D45 which showed not only potent CXCR2 antagonist activity with an IC50 value of 10 nM and 910-fold selectivity against CXCR1, but also good in vitro anti-tumor metastatic effect in wound healing assay. Moreover, compound D45 exhibitored promising druglikeness with more than 90% bioavailability in rat. Citation Format: Wen-Hai Huang, Zhi-Long Wang, Jin-Xin Che, Hai-Chao Sheng, Feng Huang, Yong-Zhou Hu, You-Hong Hu, Xin Xie, Xiao-Wu Dong. The discovery of novel small molecular CXCR2 antagonist by using ligand-based pharmacophore model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-064.

Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor

Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy

Structure-based discovery of receptor tyrosine kinase AXL degraders with excellent anti-tumor activity by selectively degrading AXL and inducing methuosis

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (C-Met) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(quinolin-6-ylmethyl)-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1h-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment Of

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (C-Met) Kinase and Anaplastic Lymphoma Kinase (ALK).

Design, Synthesis and Biological Evaluation of Novel α‐Acyloxycarboxamide‐Based Derivatives as c‐Met Inhibitors

Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor

Discovery a series of quinazolin derivatives as potent AXL inhibitors

Discovery of Novel Inhibitors for C-Met by Virtual Screening and Pharmacophore Analysis

Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors

Pyridazinone Derivatives Displaying Highly Potent and Selective Inhibitory Activities Against C-Met Tyrosine Kinase.

Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure

Discovery of 1,5-Dihydro-4<i>H</i>-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2

Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors

Abstract LB-064: The discovery of novel small molecular CXCR2 antagonist by using ligand-based pharmacophore model

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist

Discovery of a Potent and Selective FLT3 Inhibitor ( Z )- N -(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1 H -pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia

Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations

Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors